ICVX - Icosavax: Tender Offer With Contingent Value Right

2024-02-11 06:01:19 ET

Summary

• AstraZeneca has made a tender offer to acquire Icosavax's shares for $15 per share, with a contingent value right worth up to $5.
• The CVR includes milestone payouts based on FDA approval and net sales of ICVX products in certain regions.
• The acquisition is primarily focused on Icosavax's lead candidate, IVX-A12, a potential RSV and hMPV vaccine.

AstraZeneca (NASDAQ: AZN ) has an outstanding tender offer, presumably closing February 16, to acquire all of Icosavax 's ( ICVX ) shares for $15 per share in cash, plus a non-tradable contingent value right. The contingent value right or CVR can be worth up to $5 under the right circumstances....

For further details see: